Clinical Trial
doi: 10.1016/s0022-510x(03)00009-1.
D-cycloserine for the treatment of ataxia in spinocerebellar degeneration
Affiliations
- PMID: 12736088
- DOI: 10.1016/s0022-510x(03)00009-1
Item in Clipboard
Clinical Trial
D-cycloserine for the treatment of ataxia in spinocerebellar degeneration
J Neurol Sci.
.
Abstract
We studied the effects of D-cycloserine, a partial NMDA receptor allosteric agonist, on ataxia in patients with spinocerebellar degeneration. Fifteen Japanese ataxic patients enrolled in a 14-day single-blind trial of D-cycloserine (daily oral dose of 50 mg) following a 14-day single-blind placebo phase. At the end of the D-cycloserine administration, there was a significant reduction in the posture, gait and total score of the international cooperative ataxia rating scale and in the time for walking and speech tasks. D-Cycloserine was well-tolerated and no adverse effect was observed. D-Cycloserine may have therapeutic efficacy for spinocerebellar ataxia.
Similar articles
-
Pharmacological treatments of cerebellar ataxia.Cerebellum. 2004;3(2):107-11. doi: 10.1080/147342204100032331. Cerebellum. 2004. PMID: 15233578 Review.
-
The stereo-specific effect of D-serine ethylester and the D-cycloserine in ataxic mutant mice.Brain Res. 1998 Oct 12;808(1):42-7. doi: 10.1016/s0006-8993(98)00810-5. Brain Res. 1998. PMID: 9795125
-
Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.Am J Psychiatry. 2002 Mar;159(3):480-2. doi: 10.1176/appi.ajp.159.3.480. Am J Psychiatry. 2002. PMID: 11870017 Clinical Trial.
-
A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.Arch Gen Psychiatry. 1999 Jan;56(1):21-7. doi: 10.1001/archpsyc.56.1.21. Arch Gen Psychiatry. 1999. PMID: 9892252 Clinical Trial.
-
Effects of D-cycloserine on negative symptoms in schizophrenia.Schizophr Res. 2004 Dec 1;71(2-3):239-48. doi: 10.1016/j.schres.2004.03.013. Schizophr Res. 2004. PMID: 15474895 Review.
Cited by
-
Depression of extra-cellular GABA and increase of NMDA-induced nitric oxide following acute intra-nuclear administration of alcohol in the cerebellar nuclei of the rat.Cerebellum. 2005;4(4):230-8. doi: 10.1080/14734220500243835. Cerebellum. 2005. PMID: 16321878
-
Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes.Cochrane Database Syst Rev. 2014 Oct 28;2014(10):CD008953. doi: 10.1002/14651858.CD008953.pub2. Cochrane Database Syst Rev. 2014. PMID: 25348587 Free PMC article.
-
Pharmacological treatments of cerebellar ataxia.Cerebellum. 2004;3(2):107-11. doi: 10.1080/147342204100032331. Cerebellum. 2004. PMID: 15233578 Review.
-
Assessing the efficacy of specific cerebellomodulatory drugs for use as therapy for spinocerebellar ataxia type 1.Cerebellum. 2013 Feb;12(1):74-82. doi: 10.1007/s12311-012-0399-x. Cerebellum. 2013. PMID: 22718440
-
Molecular mechanism of Spinocerebellar Ataxia type 6: glutamine repeat disorder, channelopathy and transcriptional dysregulation. The multifaceted aspects of a single mutation.Front Cell Neurosci. 2015 Feb 16;9:36. doi: 10.3389/fncel.2015.00036. eCollection 2015. Front Cell Neurosci. 2015. PMID: 25762895 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
